Biotech News

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Harmony Biosciences (HRMY)Harmony Biosciences2026-06-25 13:46 ESTCompany update

WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy On Track to Extend the Pitolisant Franchise into the 2040s With Next-Gen Pitolisant Formulations Potential Best-In-Class Orexin-2 Agonist

Open original release

Related news

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

HRMYHarmony Biosciences2026-06-25 13:46 EST

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

View all latest news

Harmony Biosciences

Harmony Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

HRMYHarmony Biosciences2026-06-26 08:51 EST

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

HRMYHarmony Biosciences2026-06-26 08:51 EST

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

HRMYHarmony Biosciences2026-06-26 08:51 EST

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

HRMYHarmony Biosciences2026-06-26 08:51 EST

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

HRMYHarmony Biosciences2026-06-26 08:51 EST

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States